Patent Title:

-- Neuroprotective spirostenol pharmaceutical compositions.
-- Methods and compositions for modulating serum cortisol levels.

Journals:

-- Journal of Neurochemistry, 2002, 83:1110-1119
-- Endocrine Society 2003, abstract.

Stem Cell Therapy for Alzheimer's, Neuron Differentiation

Background: Stem cell therapy, the manipulation of stem cells to combat disease, is on the threshold of a new era in medicine. Neuronal stem cells can be induced to rapidly differentiate to adult neuron cells as a novel treatment for Alzheimer's.

Promising Stem Cell Drug Candidates:

-- SP222b
-- SP237

New Alzheimer's Pharmacologic (Rat) Model Tool:

Brand New Tool-Used by pharmaceuticals to test their preventive, stabilizing or curative therapies under development for Alzheimer's. Advantage: Pharmacologic. Only four weeks to induce full blown Alzheimer's disease compared to lengthy transgenics.

Alzheimer's Predictive Diagnostic: Advantage: Simple blood test with 70% success rate.

Patent Title:

-- Neurosteroids: Markers of Alzheimer's disease pathology

Journals:

-- Neurobiology of Aging, 2003, 24:57-65.

AIDS Related Dementia Research and Drug Candidates

Background: Elevated cortisol levels are associated with many disease states of which AIDS Related Dementia is included. SP001 has proven to be a safe and effective cortisol modulator; therefore, SP001 and its bioequivalents could change the way patients are treated, either as a single agent or in combination with other conventional therapies for AIDS.

Promising AIDS and Related Dementia Drug Candidates:

-- SP001
-- SP010
-- SP014
-- SP016
-- SP017

Patent Titles:

-- Protected Complex of Procaine .......
-- Composition of Anti-HIV Drugs and Anticortisol Compounds ..........
-- Methods and Compositions for Modulating Serum Cortisol Levels ....

Proof of Concept HIV FDA Phase II Study Results

-- Safe, Tolerable, CD8 improvement, Cortisol modulation.
-- Statistically Significant
1. Decreased HIV symptoms (Whalen Scale-Quality of Life)
2. Decreased viral load.
-- Orphan drug status requested

"We have yet to meet a Pharma executive who wasn't impressed with our science pipeline," commented Dr. Janet Greeson, Chairman, President and CEO of Samaritan. "We have a compelling story to present and the climate for partnering deals is warming up with a keener focus on new drug products and new ways to attack disease."

(Photo: http://www.newscom.com/cgi-bin/prnh/20030129/SPHCLOGO ) About Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, in collaboration with Georgetown University, is working to commercialize superior new drugs that improve the quality of life and overall health of suffering patients. The Company's compelling platform technology is based on the stress hormone cortisol and its modulation. The current development programs focus on promising new neuroprotective drugs for memory loss and Alzheimer's and include "significant" positive results for its HIV FDA/Phase II clinical trial; an Alzheimer's rat model to test new drugs; an Alzheimer's Theragnostic; a Breast Cancer Theragnostic; and a Cholesterol binding Peptide.

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed May 15, 2003. The company undertakes no duty to update forward-looking statements.

Contact: Samaritan Pharmaceuticals, Inc., 702/735-7001, Fax 702/737-7016 Gene Boyle, Business Development, Email GeneBoyle@aol.com Doug Bessert, Investor Relations, Email DougBessert@aol.com

To receive future press releases and newsletters automatically, or for more information, visit our Web site at http://www.samaritanpharmaceuticals.com/ .

CONTACT: Gene Boyle, CFO of Samaritan Pharmaceuticals Inc., +1-702-735-7001, or +1-702-499-8652, fax +1-702-737-7016, GeneBoyle@aol.com

Web site: http://www.samaritanpharma.com/

Company News On-Call: http://www.prnewswire.com/comp/158311.html
News Home
More Immunology News

New Tech Alerts Special Offer Alerts
Receive e-mail alerts on the latest technologies in:
Sign-up to find out about special offers on products:
Apoptosis
Cell Biology & Tissue Culture
PCR/RT-PCR
Electrophoresis
Nucleic Acid Purification
Transfection
Laboratory Equipment
Immunochemicals
Software
Cloning
Protein Biochemistry
Bio-Services
Imaging Systems
Molecular Biology

Your Email Address:


HTML-Formatted
Text-Only
Tissue Culture
Array Technology
PCR
Cloning
Signal Transduction
Antibodies
Nucelic Acid Isolation
Imaging/Microscopy
Laboratory Equipment
Transfection
Protein Expression
Flow Cytometry
Robotics/Automation

Your Email Address:


HTML-Formatted
Text-Only
News Sections
Breaking News
Patent News
Clinical Trial News
Discipline
Cancer
Drug Discovery
Genomics
Immunology
Industry News
Infectious Disease
Life Science
Molecular Biology
Neuroscience
Product News
New Technologies


MagNA Pure LC
Roche Applied Science
More Info
KODAK BioMax MultiBlot Kit for Proteins
Kodak
More Info
More New Technologies
Newsletters
Stay up to date on the latest technologies and science news.

Life Science
Molecular Biology
Immunology
Neuroscience
Cancer
Cell Biology
Infectious Disease
Genomics
Drug Discovery
Industry News
Clinical Trials
Patent News
Proteomics
Your email address:
HTML-Formatted
Text-Only